SBS-101 / Skyline Biosci - LARVOL DELTA

This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: Skyline Biosciences; N=24 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Oral Cancer • CRP

This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Skyline Biosciences; Trial completion date: Apr 2021 ➔ May 2023; Trial primary completion date: Apr 2021 ➔ Apr 2023

Clinical • Trial completion date • Trial primary completion date • Oral Cancer

This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Skyline Biosciences; Trial completion date: Nov 2020 ➔ Apr 2021; Trial primary completion date: Nov 2020 ➔ Apr 2021

Clinical • Trial completion date • Trial primary completion date